Co-delivery of rituximab targeted curcumin and imatinib nanostructured lipid carriers in non-Hodgkin lymphoma cells

Abstract

The aim of the present study was production of nanostructured lipid carriers (NLCs) of curcumin and imatinib for co-administration in non-Hodgkin lymphoma cells. NLCs were prepared and conjugated to rituximab to target CD20 receptors of lymphoma cell lines. Oleic acid or Labrafac and glyceryl monostearate or lecithin were used for production of NLCs. The antibody coupling efficiency to NLCs and their physical characteristics were studied. The cytotoxicity of NLCs on Jurkat T cells (CD20 receptor negative) and Ramos B cells (CD20 receptor positive) was studied by MTT assay. The cellular uptake was determined by fluorescent microscopy. The results indicated both curcumin and imatinib targeted NLCs had a significant cytotoxic effect much higher than the free drugs and non-targeted NLCs on Ramos cells. In both cell lines, the cytotoxicity of the co-administrated drugs was significantly higher than each drug alone. In Ramos cells the co-administration of curcumin (15 mu g/ml)/imatinib (5 mu g/ml) decreased the free curcumin IC50 from 8.3 +/- 0.9 to 1.9 +/- 0.2 mu g/ml, and curcumin targeted NLCs from 6.7 +/- 0.1 to 1.3 +/- 0.2 mu g/ml. In this case the IC50 of imatinib was reduced from 11.1 +/- 0.7 to 2.3 +/- 0.1 mu g/ml and imatinib targeted NLCs from 4.3 +/- 0.1 to 1.4 +/- 0.0 mu g/ml. The co-administration of ritoximab conjugated NLCs of curcumin and imatinib may enhance cytotoxicity of imatinib in treatment of non-Hodgkin lymphoma.